STARTUPS 2024
Winner in the category "Emerging Startup"
QUASAR Therapeutics
'BioVaria 2024 was a great and valuable event for us.
It’s the perfect mix of start-ups, investors, industry and
academia representing the entire life-science ecosystem.
Many thanks to the organizers and sponsors who made
this possible.'
(Arthur Dopler and Matteo Mohr)
Winner in the category "Rising Startup"
SurvivX
'We’re extremely proud to have won the competition
in our category. It was a great networking event, very
well organized, great venue, and I have met very nice
people. I’d definitely recommend it to other start-ups
for the next years.'
(Leonie de Best)
Emerging Startups 2024
Our antibody, ATN001, is the first-in-class PD-(L)1 Sensitizer that can reprogram TME and overcome the limitation of current immuno-oncology drugs.
An epigenome editing platform technology that delivers precise and tunable control of target gene activity for precision medicine
PromentalHealth: Development of a blood test for the diagnosis and personalized treatment of Alzheimer´s Disease. Development of a prognostic blood test for Alzheimer´s Disease.
QTX is an early-stage biotech startup developing innovative regulators of the complement system.
RNhale is a biotech formulating RNA into inhalable dry powder for the next generation of inhalable gene therapeutics.
Rising Startups 2024
Great therapies and drugs are truly great if they are delivered properly. We’re developing cutting-edge Direct-to-Cell Delivery Solutions for Biomolecule Delivery.
cureVision revolutionizes analysis & diagnosis & treatment of chronic wounds with AI to enhance healthcare efficiency and reduce documentation time by 90%.
Genome Biologics is a Biotech company with the single focus to improve the lives of patients with cardiovascular disease.
SeaBeLife develops First-In-Class drugs to block cellular necrosis, protecting and regenerating major organs affected by severe pathologies.
SurvivX is a pre-clinical start-up biotech company developing a novel immunomodulatory adjuvant therapy for sepsis.
BioVaria 2024 Press Release